Hot Sale API Raw Material Clopidogrel Hydrogen Sulfate Powder CAS 135046-48-9

• Powder: Yes
• Customized: Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >96%
• Model NO.: HRk-Clopidogrel Hydrogen Sulfate
• Product Name: Clopidogrel Hydrogen
• Sample: Clopidogrel Hydrogen Valiable
• Mf: C13h19no4s
• Appearance: White Powder
• Certificate: GMP ISO USP Bp
• Assay: 99%Min, 98.0% --101.0%
• Test: HPLC
• Brand Name: Henrikang
• Type of Product: Auxiliaries and Other Medicinal Chemicals
• Storage: Cool Dry Place
• Shelf Life: 2 Years Proper Storage
• Application: Raw Materials
• Grade Standard: Food Grade, Medicine Grade
• Active Ingredient: Clopidogrel Hydrogen Sulfate
• Model Number: Hrk-Clopidogrel Hydrogen
• Transport Package: 1kg Per Foil Bag, 10 Bags Per Carton. 25 Kg Per Dr
• Specification: 99%
• Trademark: Henrikang
• Origin: Shaanxi China
• Production Capacity: 500000kg/Year

Product Description

 

Hot Sale API Raw Material Clopidogrel Hydrogen Sulfate Powder CAS 135046-48-9

Doxylamine succinate	Clopidogrel Hydrogen
Appearance	white Powder
Assay	99%min, 98.0% --101.0%
Test	HPLC
Certificate	ISO 9001
CAS	135046-48-9
MF	C13h19no4s
Storage Temperature	Cool Dry Place

What is  Clopidogrel Hydrogen? Clopidogrel is an effective antiplatelet agent useful for the treatment of ischemic cerebrovascular, cardiac, and peripheral arterial disease.

   

Fuction and Application of  Clopidogrel Hydrogen

Clopidogrel is an oral, thienopyridine class antiplatelet agent used to inhibit blood clots in coronary artery disease,
peripheral vascular disease, and cerebrovascular disease. The drug works by irreversibly inhibiting a receptor called
P2Y12, an adenosine diphosphate (ADP) chemoreceptor on platelet cell membranes. Adverse effects include
hemorrhage, severe neutropenia, and thrombotic thrombocytopenic purpura (TTP).
 

Clopidogrel is used in the prevention of atherothrombotic events in the following patients:
1. Patients with myocardial infarction (from a few days to less than 35 days), patients with ischemic stroke (from 7 days
to less than 6 months), or patients with confirmed peripheral arterial disease.
2, patients with acute coronary syndrome
Non-ST-segment elevation acute coronary syndrome (including unstable angina or non-Q-wave myocardial infarction),
including patients with stent placement after percutaneous coronary intervention, in combination with aspirin.
 For patients with ST-segment elevation acute coronary syndrome, combined with aspirin, can be combined for use in
thrombolytic therapy.